BioRestorative Therapies to present new data at ORS PSRS symposium

BioRestorative Therapies (BRTX) announced that new preliminary 26-52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease, cLDD, will be presented by Francisco Silva, Vice President of Research and Development, at the Orthopaedic Research Society, ORS, Philadelphia Spine Research Society, PSRS, 7th International Spine Research Symposium, taking place November 10-14, 2024 in Skytop, Pennsylvania. BioRestorative will also make the data available through a public announcement. The safety and efficacy of BRTX-100 in treating cLDD is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study.